Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer

被引:5
|
作者
Akinwunmi, Babatunde O. [1 ,2 ]
Babic, Ana [3 ,4 ]
Vitonis, Allison F. [1 ]
Cramer, Daniel W. [1 ,5 ,6 ]
Titus, Linda [7 ,8 ]
Tworoger, Shelley S. [5 ,9 ]
Terry, Kathryn L. [1 ,5 ,6 ]
机构
[1] Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Dept Global & Continuing Educ, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Med Sch, Boston, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[6] Harvard Med Sch, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA
[7] Geisel Sch Med Dartmouth, Dept Epidemiol, Hanover, NH USA
[8] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
关键词
ANTIGEN; 125; LEVELS; SERUM CA-125; HEART-FAILURE; TUMOR-MARKERS; CARBOHYDRATE ANTIGEN-125; INFLAMMATORY ACTIVATION; HIGH-RISK; PROSTATE; LUNG; EPIDEMIOLOGY;
D O I
10.1158/1055-9965.EPI-18-0203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer. Methods: We used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA12511 assay and calculated the association between medical conditions and log-transformed CA125 using linear regression. Results: The median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/nil, for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps (P = 0.06) and hysterectomy (P = 0.01) and significantly higher with endometriosis (P 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) (P < 0.01, n 2 cases) but not among postmenopausal with CM (n 79). Furthermore, among postmenopausal women, CA1.25 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis (P = 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease (P = 0.04). Conclusions: Several chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening. Impact: Consideration of chronic medical conditions may he necessary to interpret CA125 values. (C) 2018 AACR.
引用
收藏
页码:1483 / 1490
页数:8
相关论文
共 50 条
  • [21] Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer
    Chen, Kowa
    Gentry-Maharaj, Aleksandra
    Burnell, Matthew
    Steentoft, Catharina
    Marcos-Silva, Lara
    Mandel, Ulla
    Jacobs, Ian
    Dawnay, Anne
    Menon, Usha
    Blixt, Ola
    JOURNAL OF PROTEOME RESEARCH, 2013, 12 (03) : 1408 - 1418
  • [22] Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer
    Arits, A. H. M. M.
    Stoot, J. E. G. M.
    Botterweck, A. A. M.
    Roumen, F. J. M. E.
    Voogd, A. C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) : 621 - 628
  • [23] Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
    Tcherkassova, Janneta
    Abramovich, Carolina
    Moro, Rafael
    Chen, Chen
    Schmit, Ralph
    Gerber, Angela
    Moro, Ricardo
    TUMOR BIOLOGY, 2011, 32 (04) : 831 - 838
  • [24] Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
    Gentry-Maharaj, Aleksandra
    Blyuss, Oleg
    Ryan, Andy
    Burnell, Matthew
    Karpinskyj, Chloe
    Gunu, Richard
    Kalsi, Jatinderpal K.
    Dawnay, Anne
    Marino, Ines P.
    Manchanda, Ranjit
    Lu, Karen
    Yang, Wei-Lei
    Timms, John F.
    Parmar, Max
    Skates, Steven J.
    Bast, Robert C., Jr.
    Jacobs, Ian J.
    Zaikin, Alexey
    Menon, Usha
    CANCERS, 2020, 12 (07) : 1 - 12
  • [25] Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer
    Kang, Woo Dae
    Choi, Ho Sun
    Kim, Seok Mo
    GYNECOLOGIC ONCOLOGY, 2010, 116 (01) : 57 - 60
  • [26] Human kallikrein related peptidases 6 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone
    White, Nicole M. A.
    Mathews, Maria
    Yousef, George M.
    Prizada, Amrah
    Fontaine, Daniel
    Ghatage, Prafull
    Popadiuk, Catherine
    Dawson, Lesa
    Dore, Jules J. E.
    CANCER BIOMARKERS, 2009, 5 (06) : 279 - 287
  • [27] CA125 levels among patients with advanced heart failure: An emerging independent predictor for survival
    Turgut, Okan
    Tandogan, Izzet
    Yilmaz, Mehmet Birhan
    Gul, Ibrahim
    Gurlek, Ahmet
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 145 (01) : 71 - 71
  • [28] Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
    Gupta, Digant
    Lis, Christopher G.
    JOURNAL OF OVARIAN RESEARCH, 2009, 2 (01)
  • [29] More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis
    Bast, Robert C., Jr.
    Spriggs, David R.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (03) : 429 - 430
  • [30] Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer
    Jordens, Christopher F. C.
    Morrell, Bronwen
    Harnett, Paul
    Hobbs, Kim
    Mason, Catherine
    Kerridge, Ian H.
    SOCIAL SCIENCE & MEDICINE, 2010, 71 (09) : 1548 - 1556